Table 3.
Clinical characteristics of the training set.
| Clinical characteristics | Before matching | P value | After matching | P value | ||
|---|---|---|---|---|---|---|
| CPC group (n=312) | PPC group (n=495) | CPC group (n=192) | PPC group (n=282) | |||
| Age (years) | 64 (58-69) | 65 (59-70) | 0.207 | 64 (58-70) | 65 (61-70) | 0.254 |
| Sex (%) | <0.001 | 0.800 | ||||
| Male | 269 (86.2) | 320 (64.6) | 153 (79.7) | 222 (78.7) | ||
| Female | 43 (13.8) | 175 (35.4) | 39 (20.3) | 60 (21.3) | ||
| Hypertension (%) | 54 (17.3) | 84 (17.0) | 0.901 | 30 (15.6) | 50 (17.7) | 0.548 |
| Diabetes (%) | 29 (9.3) | 33 (6.7) | 0.172 | 15 (7.8) | 21 (7.4) | 0.883 |
| Coronary heart disease (%) | 15 (4.8) | 15 (3.0) | 0.194 | 9 (4.7) | 9 (3.2) | 0.403 |
| Smoking history (%) | 152 (48.7) | 358 (72.3) | <0.001 | 77 (40.1) | 98 (34.8) | 0.236 |
| PE (%) | 48 (15.4) | 67 (13.5) | 0.464 | 24 (12.5) | 43 (15.2) | 0.399 |
| Location (%) | 0.458 | 0.494 | ||||
| Left | 131 (42.0) | 221 (44.6) | 77 (40.1) | 122 (43.3) | ||
| Right | 181 (58.0) | 274 (55.4) | 115 (59.9) | 160 (56.7) | ||
| Histology (%) | <0.001 | 0.074 | ||||
| NSCLC | 194 (62.2) | 444 (89.7) | 160 (83.3) | 251 (89.0) | ||
| SCLC | 118 (37.8) | 51 (10.3) | 32 (16.7) | 31 (11.0) | ||
| Therapy | 0.157 | |||||
| Chemotherapy regimens | 292 (93.6) | 438 (88.5) | <0.001 | 175 (91.1) | 254 (90.1) | |
| Paclitaxel | 41 (13.1) | 31 (6.3) | 27 (14.1) | 24 (8.5) | ||
| Others | 251 (80.4) | 407 (82.2) | 148 (77.1) | 230 (81.6) | ||
| Non-chemotherapy | 20 (6.4) | 57 (11.5) | 17 (8.9) | 28 (9.9) | ||
| CRP (mg/L) | 5.26 (1.43-15.77) | 2.64 (0.86-10.60) | <0.001 | 4.20 (1.18-14.70) | 4.20 (1.22-14.55) | 1.000 |
| Potassium (mmol/L) | 4.1 (3.9-4.4) | 4.1 (3.8-4.3) | 0.461 | 4.1 (3.9-4.4) | 4.1 (3.9-4.4) | 0.983 |
| TTE | ||||||
| LAD (mm) | 35 (32-38) | 34 (32-37) | 0.026 | 35 (32-37) | 34 (32-37) | 0.735 |
| LVESD (mm) | 29 (27-30) | 28 (26-30) | 0.012 | 29 (26-30) | 28 (26-30) | 0.480 |
| LVEDD (mm) | 47 (45-49) | 47 (44-49) | 0.11 | 47 (44-49) | 47 (44-49) | 0.437 |
| LVEF (%) | 64 (62-65) | 64 (62-65) | 0.773 | 64 (62-65) | 64 (62-65) | 0.522 |
| NOAF (%) | 54 (17.3) | 35 (7.1) | <0.001 | 32 (16.7) | 21 (7.4) | 0.002 |
Data are presented as median (interquartile range) or n (%). CPC, centric pulmonary carcinoma; PPC, peripheral pulmonary carcinoma; PE, pericardial effusion; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CRP, c-reactive protein; TTE, transthoracic echocardiography; LAD, left atrial diameter; LVESD, left ventricular end diastolic diameter; LVEDD, left ventricular end diastolic diameter;LVEF, left ventricular ejection fraction; NOAF, new-onset atrial fibrillation.